Niagen Bioscience Inc

Research Niagen Bioscience Inc (NAGE) on Bullrun: valuation model: 36.6% undervalued, market cap USD 262.83M, P/E 15.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNAGE
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal36.6% undervalued
• Market capUSD 262.83M
• P/E15.1
• Financial periodFY2025
• RevenueUSD 129.42M
• Revenue growth29.9%
• Net incomeUSD 17.38M
• Gross margin64.3%

Valuation Snapshot

Bullrun's latest valuation model marks Niagen Bioscience Inc as 36.6% undervalued; latest market cap is USD 262.83M; P/E is 15.1.

About Niagen Bioscience Inc

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism;

Frequently asked questions

Is Niagen Bioscience Inc overvalued or undervalued?

Bullrun's valuation model currently marks Niagen Bioscience Inc as 36.6% undervalued.

What is Niagen Bioscience Inc's market cap?

Niagen Bioscience Inc's market capitalization is USD 262.83M.

What is Niagen Bioscience Inc's P/E ratio?

Niagen Bioscience Inc's price-to-earnings (P/E) ratio is 15.1.

What does Niagen Bioscience Inc do?

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.